nach oben

Erschienen in:

01.12.2010 | Review

Gastrointestinal Stromal Tumors (GISTs): An Updated Experience

verfasst von: Anastasios Machairas, Eva Karamitopoulou, Dimitrios Tsapralis, Theodore Karatzas, Nickolas Machairas, Evangelos P. Misiakos

Erschienen in: Digestive Diseases and Sciences | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

Gastrointestinal stromal tumors (GISTs) are relatively common mesenchymal tumors of the digestive tract characterized by c-KIT mutations. This is a comprehensive review of the current data of the literature on the various aspects of the diagnosis and treatment of these tumors.

Methods

The stomach is the most commonly involved site for these tumors in the digestive tract. Computed tomography and endoscopy can usually establish the diagnosis. The study of certain specific immunohistochemical markers may contribute to better characterization of these tumors.

Results

Surgical resection of GISTs has been the most effective therapy. In addition, targeted therapy with tyrosine kinase inhibitors may reduce the development of recurrence or decrease the disease progression in patients with metastatic disease.

Conclusions

The introduction of tyrosine kinase inhibitors has resulted in significant improvement in the overall prognosis of these patients. Furthermore, preoperative imatinib can decrease tumor volume and is associated with complete surgical resection in locally advanced primary GISTs.

Joensuu H, Roberts PJ, Sarlomo-Rikala M. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052.PubMedCrossRef

Fletcher CDM, Berman JJ, Corless C, et al. Diagnosis of gastrointestinal tumors: a consensus approach. Hum Pathol. 2002;33:459–465.PubMedCrossRef

Tran T, Davilla JA, El-Serag HB, et al. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastronterol. 2005;100:162–168.CrossRef

Rubin BP, Heinrich MC, Corless CL, et al. Gastrointestinal stromal tumors. Lancet. 2007;369:1731–1741.PubMedCrossRef

DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;23:51–58.CrossRef

Miettinen M, Sobin LH, Sarlomo-Rikala M, et al. Immunohistochemical spectrum of GISTs at different sites and their differential diagnosis with a reference to CD117 (KIT). Mod Pathol. 2000;13:1134–1142.PubMedCrossRef

Mazur MT, Clark HB, et al. Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507–519.PubMedCrossRef

Gold J, DeMatteo R, et al. Combined surgical and molecular therapy. The gastrointestinal stromal tumor model. Ann Surg. 2006;244:176–184.PubMedCrossRef

Van der Zwan S, DeMatteo RP. Gastrointestinal stromal tumor: 5 years later. Cancer. 2005;104:1781–1788.PubMedCrossRef

10.

Miettinen M, Lasota J, et al. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med. 2006;130:1466–1478.PubMed

11.

Efron DT, Lillemoe KD, Cameron JL, et al. Surgical management of gastrointestinal stromal tumors: A single institution 33-year experience. Gastroenterology. 2001;120:41A.

12.

Roberts PJ, Eisenberg B. Clinical presentation of gastrointestinal stromal tumors and treatment of operable disease. Eur J Cancer. 2002;38:S37–S38.PubMedCrossRef

13.

Connoly EM, Gaffney E, Reynolds JV, et al. Gastrointestinal stromal tumors. Br J Surg. 2004;91:252–253.

14.

Chompret A, Kannengiesser C, Barrois M, et al. PDGFRA germline mutation in a family with multiple cases of GISTs. Gastroenterology. 2004;126:318–321.PubMedCrossRef

15.

Corless CL, Fletcher JA, Heinrich MC, et al. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–3825.PubMedCrossRef

16.

Lasota J, Miettinen M, et al. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTS). Semin Diagn Pathol. 2006;23:91–102.PubMedCrossRef

17.

Robson ME, Glogowski E, Sommer G, et al. Pleomorphic characteristics of a germline KIT mutation in a large kindred with GISTs, hyperpigmentation, and dysphagia. Clin Cancer Res. 2004;10:1250–1254.PubMedCrossRef

18.

Li FP, Fletcher JA, Heinrich MC, et al. Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred. J Clin Oncol. 2005;23:2735–2743.PubMedCrossRef

19.

Kinoshita K, Hirota S, Isozaki K, et al. Absence of c-kit gene mutations in gastrointestinal stromal tumors from neurofibromatosis type 1 patients. J Pathol. 2004;202:80–85.PubMedCrossRef

20.

Carney JA. Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney triad): Natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc. 1999;74:543–552.PubMedCrossRef

21.

Amieux PS. Getting the GIST of the Carney triad: growth factors, rare tumors, and cellular respiration. Pediatr Dev Pathol. 2004;7:306–308.PubMedCrossRef

22.

Erlandson RA, Woodruff JM, et al. Role of electron microscopy in the evaluation of soft tissue neoplasms, with emphasis on spindle cell and pleomorphic tumors. Hum Pathol. 1998;29:1372–1381.PubMedCrossRef

23.

Miettinen M, Lasota J, et al. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12.PubMedCrossRef

24.

Kindblom LG, Rmotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269.PubMed

25.

Miettinen M, Lasota J. Gastrointestinal stromal tumors: Pathology and prognosis at different sites. Semin Diagn Pathol. 2006;23:70–83.PubMedCrossRef

26.

Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pace-maker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the intestinal cells of Cajal. Am J Pathol. 1998;152:1259–1269.PubMed

27.

West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107–113.PubMed

28.

Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32:210–218.PubMedCrossRef

29.

Tsujimura T, Makiishi-Shimobayashi C, Lundvist J, et al. Expression of the intermediate filament nestin in gastrointestinal stromal tumors and intestinal cells of Cajal. Am J Pathol. 2001;158:817–823.PubMed

30.

Sarlomo-Rikala M, Tsujimura T, Lendahl U, et al. Patterns of nestin and other intermediate filament expression distinguish between gastrointestinal stromal tumors, leiomyomas and schwannomas. APMIS. 2002;110:499–507.PubMedCrossRef

31.

Blay P, Astudillo A, Buessa JM, et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res. 2004;10:4089–4095.PubMedCrossRef

32.

Motegl A, Sakurai S, Nakayama H, et al. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for intentifying KIT-negative tumors. Pathol Int. 2005;55:106–112.CrossRef

33.

Duensing A, Joseph NE, Medeiros F, et al. Protein kinase C theta (PKC theta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004;64:5127–5131.PubMedCrossRef

34.

Kirsch R, Gao ZH, Riddel R, et al. Gastrointestinal stromal tumor: diagnostic challenges and practical approach to differential diagnosis. Adv Anat Pathol. 2007;14:261–285.PubMedCrossRef

35.

Miettinen M, Lasota J. Gastrointestinal stromal tumors-definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch. 2001;438:1–12.PubMedCrossRef

36.

Dhimes P, Lopez-Carreira M, Ortega-Serrano MP, et al. Gastrointestinal autonomic nerve tumors and their separation from other gastrointestinal stromal tumors: An ultrastructural and immunohistochemical study of 7 cases. Virchows Arch. 1995;426:27–35.PubMedCrossRef

37.

Abraham SC. Distinguishing gastrointestinal stromal tumors from their mimics: an update. Adv Anat Pathol. 2007;14:178–188.PubMedCrossRef

38.

Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728–734.PubMed

39.

Perez-Atayde AR, Shamberger RC, Kozakewich HW, et al. Neuroectodermal differentiation of the gastrointestinal stromal tumors in the Carney triad. An ultrastructural and immunohistochemical study. Am J Surg Pathol. 1993;17:706–714.PubMedCrossRef

40.

Qiu FH, Ray P, Brown K, et al. Primary structure of c-KIT: relationship with the CSF-1/PDGF receptor kinase family-oncogenic activation of v-kit involves deletion of extracellular domain and C terminus. EMBO J. 1988;7:1003–1011.PubMed

41.

Liegl-Atzwanger B, Fletcher JA, Fletcher CDM. Gastrointestinal stromal tumors. Virchows Arch. 2010;456:111–127.PubMedCrossRef

42.

Fleischman RA. From white spots to stem cells: The role of the KIT receptor in mammalian development. Trends Genet. 1993;9:285–290.PubMedCrossRef

43.

Ward SM, Burns AJ, Torihashi S, et al. Mutation of the proto-oncogene c-kit blocks development of interstitial cells and electrical rhythmicity in murine intestine. J Physiol. 1994;480:91–97.PubMed

44.

Tian Q, Frierson HFJ, Krystal GW, et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol. 1999;154:1643–1647.PubMed

45.

Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res. 2001;61:8118–8121.PubMed

46.

Rossi CR, Mocellin S, Mencarelli R, et al. Gastrointestinal stromal tumors: From a surgical to a molecular approach. Int J Cancer. 2003;107:171–176.PubMedCrossRef

47.

Connolly EM, Gaffney E, Reynolds JV, et al. Gastrointestinal stromal tumors. Br J Surg. 2003;90:1178–1186.PubMedCrossRef

48.

Isozaki K, Terris B, Belghiti J. Germline-activating mutation in the kinase domain of KIT gene in familial gastrointestinal stromal tumors. Am J Pathol. 2000;157:1581–1585.PubMed

49.

Bauer S, Corless CL, Heinrich MC, et al. Response to imatinib mesylate of a gastrointestinal stromal tumor with very low expression of KIT. Cancer Chemother Pharmacol. 2003;51:261–265.PubMed

50.

Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic complications. Am J Surg Pathol. 2004;33:484–495.

51.

Heinrich MC, Rubin BP, Longley BJ, et al. Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations. Hum Pathol. 2002;33:484–495.PubMedCrossRef

52.

Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708–710.PubMedCrossRef

53.

Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660–667.PubMedCrossRef

54.

Boccon-Gibod L, Boman F, Boudjemaa S, et al. Separate occurrence of extra-adrenal paraganglioma and gastrointestinal stromal tumor in monozygotic twins: probable familial Carney syndrome. Pediatr Dev Pathol. 2004;7:380–384.PubMedCrossRef

55.

Lerma E, Lee SJ, Tugues D, et al. Ploidy of 36 stromal tumors of the gastrointestinal tract: A comparative study with flow cytometry and image analysis. Anal Quant Cytol Histol. 1994;16:435–440.PubMed

56.

Rudolph P, Gloeckner K, Parwaresch R, et al. Immunophenotype, proliferation, DNA ploidy, and biological behavior of gastrointestinal stromal tumors: A multivariate clinicopathologic study. Hum Pathol. 1998;29:791–800.PubMedCrossRef

57.

House MG, Guo MZ, Efron DT, et al. Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior. J Gastroint Surg. 2003;7:1004–1014.CrossRef

58.

Sakurai S, Fukayama M, Kaizaki Y, et al. Telomerase activity in gastrointestinal stromal tumors. Cancer. 1998;83:2060–2066.PubMedCrossRef

59.

Vrettou E, Karkavelas G, Christoforidou B, et al. Immunohistochemical phenotyping and DNA detection in gastrointestinal stromal tumors. Anticancer Res. 1995;15:943–950.PubMed

60.

Yu CC, Fletcher CD, Newman PL, et al. A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumors. J Pathol. 1992;166:147–152.PubMedCrossRef

61.

Kontogianni K, Demonakou M, Kavantzas N, et al. Prognostic predictors of gastrointestinal stromal tumors: A multi-institutional analysis of 102 patients with definition of a prognostic index. Eur J Surg Oncol 2003; 29:548-556.

62.

Koon N, Schneider-Stock R, Sarlomo-Rikala M, et al. Molecular targets for tumor progression in gastrointestinal stromal tumors. Gut. 2004;53:235–240.PubMedCrossRef

63.

Andersson J, Bumming P, Meis-Kindblom JM, et al. Gstrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology. 2006;130:1573–1581.PubMedCrossRef

64.

Chirieac LR, Trent JC, Steinert DM, et al. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer. 2006;107:2237–2244.PubMedCrossRef

65.

Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557–558 of the c-kit gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol. 2005;23:6190–6198.PubMedCrossRef

66.

Tateishi U, Hasegawa T, Satake M, et al. Gastrointestinal stromal tumors: Correlation of computed tomography findings with tumor grade and mortality. J Comput Assist Tomogr. 2003;27:792–798.PubMedCrossRef

67.

Burkill GJC, Badran M, Al-Muderis O, et al. Malignant gastrointestinal stromal tumor: Distribution, imaging findings, and pattern of metastatic spread. Radiology. 2003;226:527–532.PubMedCrossRef

68.

Gong JS, Zuo M, Yang P, et al. Value of CT in the diagnosis and follow-up of gastrointestinal stromal tumors. Clin Imaging. 2008;32:172–177.PubMedCrossRef

69.

Scarpa M, Bertin M, Ruffolo C, et al. A systematic review of the clinical diagnosis of gastrointestinal stromal tumors. J Surg Oncol. 2008;98:384–392.PubMedCrossRef

70.

Logrono R, Bhanot P, Chaya C, et al. Imaging, morphology, and immunohistochemical correlation in gastrointestinal stromal tumors. Cancer. 2006;108:257–266.PubMedCrossRef

71.

Ghanem N, Altehoefer C, Furtwangler A, et al. Computed tomography in gastrointestinal stromal tumors. Eur Radiol. 2003;13:1669–1678.PubMedCrossRef

72.

Sandrasegaran K, Rajesh A, Rushing DA, et al. Gastrointestinal stromal tumors: CT and MRI findings. Eur Radiol. 2005;15:1407–1414.PubMedCrossRef

73.

Matsui M, Goto H, Niwa Y, et al. Preliminary results of fine-needle aspiration biopsy histology in upper gastrointestinal submucosal tumors. Endoscopy. 1998;30:750–755.PubMedCrossRef

74.

Chu HJ, Byun JY, Chun KA, et al. Gastrointestinal leiomyoma and leiomyosarcoma: CT differentiation. J Comput Assist Tomogr. 1998;22:69–74.CrossRef

75.

Horton KM, Juluru K, Montogomery E, et al. Computed tomography imaging of gastrointestinal stromal tumors with pathology correlation. J Comput Assist Tomogr. 2004;28:811–817.PubMedCrossRef

76.

Levy AD, Remotti HE, Thompson WM, et al. Gastrointestinal stromal tumors: radiologic features and pathologic correlation. Radiographics. 2003;23:283–304.PubMedCrossRef

77.

Choi H, et al. Response evaluation of gastrointestinal stromal tumors. Oncologist. 2008;2:4–7.CrossRef

78.

Holdsworth CH, Badawi RD, Manola JB, et al. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. Am J Roentgenol. 2007;189:324–330.CrossRef

79.

Heinicke T, Wardelmann E, Sauerbruch T. et al. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumors using 18fluorodeoxyglucose-positron emission tomography. Anticancer Res. 2005;2(5):4591–4594.

80.

Basu S, Mohandas KM, Peshive H, Asopa R, Unawahare M, et al. FDG-PET and PET-CT in the clinical management of GISTs. Nucl Med Commun. 2008;29:1026–1039.PubMedCrossRef

81.

Antoch G, Kanja J, Bauer S, et al. Comparison of PET, CT and dual modality PET/CT imaging for monitoring imatinib (STI571) therapy in patients with GISTs. J Nucl Med. 2004;45:357–365.PubMed

82.

Everett M, Gutman H, et al. Surgical management of gastrointestinal stromal tumors: Analysis of outcome with respect to surgical margins and technique. J Surg Oncol. 2008;98:588–593.PubMedCrossRef

83.

Wang S, et al. Surgical management of gastrointestinal stromal tumors. Zhonghua Wei Chang Wai Ke Za Zhi. 2007;10:5–7.PubMed

84.

Bonvalot S. An update of the surgical indications for gastrointestinal stromal tumors. J Chir (Paris) 2008;3:6S8–11.

85.

Demetri GD, Benjamin RS, Blanke CD, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)—update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007; 5(Suppl2):S1–29.

86.

Ng EH, Pollock RE, Romsdahl MM, et al. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer. 1992;69:1334–1341.PubMedCrossRef

87.

Chen H, Pruitt A, Nicol TL, et al. Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg. 1998;2:151–155.PubMedCrossRef

88.

Aparicio T, Boige V, Sabourin JC, et al. Prognostic factors after surgery of primary resectable gastrointestinal stromal tumors. Eur J Surg Oncol. 2004;30:1098–1103.PubMedCrossRef

89.

Blum MG, Bilimoria KY, Wayne JD, et al. Surgical considerations for the management and resection of esophageal gastrointestinal stromal tumors. Ann Thorac Surg. 2007;84:1717–1723.PubMedCrossRef

90.

Otani Y, Furukawa T, Yoshida M, et al. Operative indications for relatively small (2–5cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operative cases. Surgery. 2006;139:484–492.PubMedCrossRef

91.

Winfield RD, Hochwald SN, Vogel SB, et al. Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg. 2006;72:719–722.PubMed

92.

Dematteo RP, Maki RG, Antonescu C, et al. Targeted molecular therapy for cancer: the application of STI571 to gastrointestinal stromal tumor. Curr Probl Surg. 2003;40:144–193.PubMedCrossRef

93.

Novitsky YW, Kercher KW, Sing RF, et al. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg. 2006;243:738–745.PubMedCrossRef

94.

Choi SM, Kim MC, Jung GJ, et al. Laparoscopic wedge resection for gastric GIST: long-term follow up results. Eur J Surg Oncol. 2007;33:444–447.PubMedCrossRef

95.

Lai IR, Lee WJ, Yu SC, et al. Minimally invasive surgery for gastric stromal tumors: intermediate follow up results. J Gastrointest Surg. 2006;10:563–566.PubMedCrossRef

96.

Hindmarsh A, Koo B, Lewis MP, et al. Laparoscopic resection of gastric gastrointestinal stromal tumors. Surg Endosc. 2005;19:1109–1112.PubMedCrossRef

97.

Nishimura J, Nakajima K, Omori T, et al. Surgical strategy for gastric gastrointestinal stromal tumors: laparoscopic vs open resection. Surg Endosc. 2007;21:875–878.PubMedCrossRef

98.

Joensuu H, Fletcher C, Dimitrijevic S, et al. Management of malignant gastrointestinal stromal tumors. Lancet Oncol. 2002;3:655–664.PubMedCrossRef

99.

Pierie JP, Choudry U, Muzikansky A, et al. The effect of surgery and grade on outcome of gastrointestinal stromal tumors. Arch Surg. 2001;136:383–389.PubMedCrossRef

100.

Trupiano JK, Stewart RE, Misick C, et al. Gastric stromal tumors: A clinicopathologic study of 77 cases with correlation of features with nonaggressive and aggressive clinical behaviors. Am J Surg Pathol. 2002;26:705–714.PubMedCrossRef

101.

Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol. 2007;14:14–24.PubMedCrossRef

102.

Nilsson B, Sjolund K, Kindblom LG, et al. Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk GIST. Br J Cancer. 2007;96:1656–1658.PubMedCrossRef

103.

DeMatteo RP, Owzar K, Maki RG, et al. Adjuvant imatinib mesylate increases recurrence free survival in patients with completely resected localized primary gastrointestinal stromal tumor (GIST): North American Intergroup Phase III trial ACOSOG Z9001. Proceedings of the American Society of Clinical Oncology, 2007 ASCO Annual Meeting.

104.

DeMatteo RP, Antonescu CR, Chadaram V, et al. Adjuvant imatinib mesylate in patients with primary high risk GIST following complete resection: safety results from the U.S. Intergroup Phase II trial ACOSOG Z 9000. Proceedings of the American Society of Clinical Oncology, 2005;23(16S).

105.

Heinrich M, Griffith D, Druker B, et al. Inhibition of c-KIT receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor. Blood. 2000;96:925–932.PubMed

106.

Croom KF, Perry CM, et al. Imatinib mesylate: in the treatment of gastrointestinal stromal tumors. Drugs. 2003;63:513–522.PubMedCrossRef

107.

Tarn C, Godwin AK, et al. Molecular research directions in the management of gastrointestinal stromal tumors. Curr Treat Options Oncol. 2005;6:473–486.PubMedCrossRef

108.

Tuveson D, Willis N, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-Kit oncoprotein, biological and clinical implication. Oncogene. 2001;20:5054–5058.PubMedCrossRef

109.

Joensuu H, Roberts P. Sarlomo-Rikala, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344:1052–1056.PubMedCrossRef

110.

Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–480.PubMedCrossRef

111.

Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized trial of imatinib mesylate (STI571) for GIST: Intergroup S0033 early results. Proceedings of the American Society of Clinical Oncology, 2003;22.

112.

Verweij J, Casali PG, Zalcberg J. Progression-free survival in gastrointestinal stromal tumors with high-dose imatinib: randomized trial. Lancet. 2004;364:1127–1134.PubMedCrossRef

113.

Debiec-Rychter M, Dumez H, Judson I, et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumors entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40:689–695.PubMedCrossRef

114.

Blay JY, Le Cense A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol. 2007;25:1107–1113.PubMedCrossRef

115.

Rutkowski P, Symonides M, Zdzienicki M, Siedlecki JA, et al. Developments in targeted therapy of advanced gastrointestinal tumors. Recent Patents Anticancer Drug Discov. 2008;3:88–99.CrossRef

116.

Van Glabbeke M, Verweij J, Casali PG, et al. Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study. J Clin Oncol. 2005;23:5795–5804.PubMedCrossRef

117.

Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–4349.PubMedCrossRef

118.

Lim KH, Huanq MJ, Chen LT, et al. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med Oncol. 2008;25:207–213.PubMedCrossRef

119.

Aqaram NP, Wonq GC, Guo T, et al. Novel V600E mutations in imatinib-naïve and imatinib-resistant GISTs. Genes Chromosomes Cancer. 2008;47:853–859.CrossRef

120.

Italiano A, Bui B. Gastrointestinal stromal tumors: molecular aspects and therapeutic implications. Bull Cancer. 2008;95:107–116.PubMed

121.

Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumors after failure of imatinib: a randomized controlled trial. Lancet. 2006;368:1329–1338.PubMedCrossRef

122.

Cassier PA, Dufresne A, Arifi S, et al. Novel approaches to gastrointestinal stromal tumors resistant to imatinib and sunitinib. Curr Gastroenterol Rep. 2008;10:555–561.PubMedCrossRef

123.

Reichardt P, et al. Novel approaches to imatinib- and sunitinib-resistant GIST. Curr Oncol Rep. 2008;10:344–349.PubMedCrossRef

124.

Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant, and palliative treatment of GISTs with imatinib: a centre-based study of 17 patients. Br J Cancer. 2003;89:460–464.PubMedCrossRef

125.

Gutierrez JC, Perez EA, Moffat FL, et al. Should soft tissue sarcomas be treated at high-volume centers? An analysis of 4205 patients. Ann Surg. 2007;245:952–958.PubMedCrossRef

Titel: Gastrointestinal Stromal Tumors (GISTs): An Updated Experience
verfasst von: Anastasios Machairas
Eva Karamitopoulou
Dimitrios Tsapralis
Theodore Karatzas
Nickolas Machairas
Evangelos P. Misiakos
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Digestive Diseases and Sciences / Ausgabe 12/2010
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-010-1360-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2010

Subclinical Intestinal Inflammation in Siblings of Children with Crohn’s Disease

The Association of Inflammatory Bowel Disease and Mediterranean Fever Gene (MEFV) Mutations in Turkish Children

Clinical Advantage of Highly Sensitive On-Chip Immunoassay for Fucosylated Fraction of Alpha-Fetoprotein in Patients with Hepatocellular Carcinoma

Rates of Surveillance and Management of Hepatocellular Carcinoma in Patients Evaluated at a Liver Transplant Center

Decreased Prohepcidin Levels in Patients with HBV-Related Liver Disease: Relation with Ferritin Levels